Semaglutide in people with obesity: boosts wellbeing and abili...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
BAGSVAERD, Denmark, May 13, 2021 /PRNewswire-AsiaNet/ -- Novo Nordisk today announced new results from the STEP phase 3a clinical trial programme, demonstrating potential benefits beyond weight loss for people with obesity being treated with semaglutide 2.4 mg. The trial showed that treatment with once-...
Authors: LATEST ASIANET NEWS RELEASES